Fondazione del Piemonte IRCCS di Candiolo Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2019
NCT03838744
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Fondazione del Piemonte IRCCS di Candiolo

Active Ingredients

Drugs in Phase 2 Trials (2)

olaparib (lynparza) (1 trial)

trabectedin (yondelis) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Sarcoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2